‘This compound really provides a fresh angle for developing drugs to treat seizures,’ says Scripps Analysis Assistant Professor Xiaoying Lu, who co-authored the paper with Professor Edward Roberts, Chair of the Molecular and Integrative Neurosciences Section Tamas Bartfai, and colleagues. As explained this week in Proceedings of the National Academy of Sciences , the new compound effectively reduced the frequency and severity of seizures in rats and mice.The relative risk between your SYMLIN and pooled comparator organizations was 0.86 . The hazard ratios for major MACE ranged from 0.88 to 0.93, with respect to the analysis method . Additional analyses of narrower and broader MACE definitions led to similar findings with the higher limit of the 95 % confidence interval below 1.8 for many CV endpoints and analysis methods. These data claim that SYMLIN treatment in sufferers with type 2 diabetes is not associated with an elevated risk of CV adverse events.